The role of bcl-2 expression in breast carcinomas (Review)

Oncology Reports

Volumn 5, Issue 5, 1998, Pages 1211-1216

  Zhang, Guo Jun ^a   Kimijima, Izo ^a   Tsuchiya, Atsuo ^a   Abe, Rikiya ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; bcl 2; Breast cancer; Prognosis; Therapy; Tumorigenesis

Indexed keywords

ONCOPROTEIN;

BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; DIAGNOSTIC VALUE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW;

EID: 0031877041     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.5.1211     Document Type: Review

References (55)

1. Wyllie AH: Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer Metastasis Rev 11: 95-103, 1992.
2. Reed JC: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. (Review). Curr Opin Oncol 7: 541-546, 1995.
3. Tsujimoto Y, Cossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443, 1985.
4. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
5. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
6. Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81: 151-157, 1993.
7. Jaattela M, Benedict M, Tewari M, Shayman JA and Dixit VM: Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10: 2297-2305, 1995.
8. Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
9. Krajewska M, Fenoglio-Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmerman G and Reed JC: Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 149: 1449-1457, 1996.
10. Sinicrope FA, Ruan S, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
11. Brocker M, De Buhr I, Papageorgiou G, Schatz H and Derwahl M: Expression of apoptosis-related proteins in thyroid tumors and thyroid carcinoma cell lines. Exp Clin Endocrinol Diabetes 4: 20-23, 1996.
12. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003-1007, 1995.
13. Ham HJ, Ho LI, Liu CA, Liu GC, Lin FG, Lin JJ, Chang JY and Lee WH: Down regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues. Histopathology 28: 317-323, 1996.
14. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S and Herman B: Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 57: 509-521, 1995.
15. Van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ and van de Vijver MJ: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74: 78-85, 1996.
16. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P and Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604-1610, 1996.
17. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
18. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P and Harris A: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27: 1149-1155, 1996.
19. Binder C, Marx D, Overhoff R, Binder L, Schauer A and Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinico-pathological variables. Ann Oncol 6: 1005-1010, 1995.
20. Siziopikou KP, Prioleau JE, Harris JR and Schnitt SJ: bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77: 499-506, 1996.
21. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994.
22. Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T and Masaoka A: Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat 42: 173-181, 1997.
23. Zhang GJ, Kimijima I, Abe R, Kanno M, Katagata N, Hara K, Watanabe T and Tsuchiya A: Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Clin Cancer Res 3: 2329-2336, 1997.
24. Ngan BY, Chen-Levy Z, Weiss LM, Wamke RA and Cleary ML: Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 318: 1638-1644, 1988.
25. Duenas-Gonzalez A, Abad-Hernandez MM, Cruz-Hernandez JJ and Gonzalez-Sarmiento R: Analysis of bcl-2 in sporadic breast carcinoma. Cancer 80: 2100-2108, 1997.
26. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
27. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
28. Joensuu H, Pylkkanen L and Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198, 1994.
29. Elledge RM and Allred DC: The p53 tumor suppressor gene in breast cancer. (Review). Breast Cancer Res Treat 32: 39-47, 1994.
30. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al: cerbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer (see comments) (published erratum appears in N Engl J Med 331: 211, 1994). N Engl J Med 330: 1260-1266, 1994.
31. Norberg T, Jansson T, Sjogren S, Martensson C, Andreasson I, Fjallskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L and Bergh J: Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. Acta Oncol 35: 96-102, 1996.
32. McConkey DJ, Greene G and Pettaway CA: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 56: 5594-5599, 1996.
33. Reed JC: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. (Review). Hematol Oncol Clin North Am 9: 451-473, 1995.
34. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young LS: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228, 1995.
35. Reed JC, Kitada S, Takayama S and Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: 61-65, 1994.
36. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blarney RW and Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
37. Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C and Miller WR: The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat 44: 123-133, 1997.
38. Gasparini G, Barbareschi M, Doglioni C, Dalla Palma P, Angelo Mauri F, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F and Harris AL: Expression of bcl-2 protein predicts efficacy of adjuvant treatment in operable node-positive breast cancer. Clin Cancer Res 1: 189-198, 1995.
39. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S and Osborne CK: bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 15: 1916-1922, 1997.
40. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A and Bhalla K: Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42: 73-81, 1997.
41. Perry RR, Kang Y and Greaves BR: Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72: 1441-1446, 1995.
42. Colletti RB, Roberts JD, Devlin JT and Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 49: 1882-1884, 1989.
43. Kang Y, Cortina R and Perry RR: Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst 88: 279-284, 1996.
44. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M and Fabra A: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60, 1995.
45. Van Slooten HJ, van de Vijver MJ, van de Velde CJ and van Dierendonck JH: Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77: 789-796, 1998.
46. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H and Hirohashi S: Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 27: 371-377, 1997.
47. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, et al: Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol 5: 409-414, 1994.
48. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P and van Marck E: Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 72: 354-360, 1995.
49. Berardo MD, Elledge RM, De Moor C, Clark GM, Osbome CK and Allred DC: bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82: 1296-1302, 1998.
50. O'Reilly LA, Huang DC and Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15: 6979-6990, 1996.
51. Reed JC: Promise and problems of bcl-2 antisense therapy. J Natl Cancer Inst 89: 988-990, 1997.
52. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA and Zangemeister-Writtke U: Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89: 1027-1036, 1997.
53. Kitada S, Miyashita T, Tanaka S and Reed JC: Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 3: 157-169, 1993.
54. Webb A, Cunningham D, Cotter F, Clarke PA, Di Stefano F, Ross P, Corbo M and Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137-1141, 1997.
55. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K and Tsuchiya A: Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res (In press).